Javascript must be enabled to continue!
Abstract 4144947: Invasive Hemodynamic Validation of a Novel Echocardiographic Artificial Intelligence Screening Tool for HFpEF
View through CrossRef
Background:
Right heart catheterization (RHC) is the gold standard for diagnosing heart failure with preserved ejection fraction (HFpEF). An FDA-approved artificial intelligence (AI) technology uses a four-chamber transthoracic echocardiogram (TTE) image to screen patients for HFpEF.
Methods:
We compared invasive hemodynamic data between patients screened for HFpEF by this TTE AI algorithm. We retrospectively collected data from two cohorts of patients with an ejection fraction (EF) ≥ 50% undergoing RHC for the evaluation of HFpEF. The most recent TTE was screened using the AI tool and reported as either suggestive or non-suggestive for HFpEF – labeled as “positive” or “negative,” respectively. Invasive hemodynamic parameters at rest and during exercise were collected. Positive and negative groups were compared using Student’s t-test and Mann-Whitney U test.
Results:
A total of 47 patients (82% women, 79% Black, average EF 62%) had a previous RHC, with 23 undergoing subsequent exercise RHC. There were 18 patients (38%) with a positive AI result and 29 (62%) negative. Positive patients had significantly higher rates of atrial fibrillation (38% vs 11%, p=.03), NT-proBNP levels (median 451 vs 117 ug/mL, p=.001), and H2FPEF (median 6 vs 4, p<.001) and HFA-PEFF scores (median 5 vs 2, p=.005). Of 18 positive patients, 16 (89%) had a resting pulmonary capillary wedge pressure (PCWP) > 15 mmHg, consistent with HFpEF, compared to only 14 of 28 (50%) negative patients. With exercise 6 of 7 (86%) positive patients had PCWP ≥ 25 mmHg, consistent with HFpEF, compared to 11 of 20 (55%) negative patients. At rest, positive patients had significantly higher PCWP, mean pulmonary arterial pressure (mPAP), and pulmonary vascular resistance (PVR). After exercise, there were no significant differences in PCWP or mPAP between the two groups, but thermodilution cardiac output was significantly lower in the positive patients.
Conclusion:
Patients identified as HFpEF positive by a validated TTE-guided AI tool were more likely to have HFpEF confirmed invasively, indicating its potential for risk stratification. However, the negative predictive value for HFpEF confirmed by invasive hemodynamics was low in this population.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 4144947: Invasive Hemodynamic Validation of a Novel Echocardiographic Artificial Intelligence Screening Tool for HFpEF
Description:
Background:
Right heart catheterization (RHC) is the gold standard for diagnosing heart failure with preserved ejection fraction (HFpEF).
An FDA-approved artificial intelligence (AI) technology uses a four-chamber transthoracic echocardiogram (TTE) image to screen patients for HFpEF.
Methods:
We compared invasive hemodynamic data between patients screened for HFpEF by this TTE AI algorithm.
We retrospectively collected data from two cohorts of patients with an ejection fraction (EF) ≥ 50% undergoing RHC for the evaluation of HFpEF.
The most recent TTE was screened using the AI tool and reported as either suggestive or non-suggestive for HFpEF – labeled as “positive” or “negative,” respectively.
Invasive hemodynamic parameters at rest and during exercise were collected.
Positive and negative groups were compared using Student’s t-test and Mann-Whitney U test.
Results:
A total of 47 patients (82% women, 79% Black, average EF 62%) had a previous RHC, with 23 undergoing subsequent exercise RHC.
There were 18 patients (38%) with a positive AI result and 29 (62%) negative.
Positive patients had significantly higher rates of atrial fibrillation (38% vs 11%, p=.
03), NT-proBNP levels (median 451 vs 117 ug/mL, p=.
001), and H2FPEF (median 6 vs 4, p<.
001) and HFA-PEFF scores (median 5 vs 2, p=.
005).
Of 18 positive patients, 16 (89%) had a resting pulmonary capillary wedge pressure (PCWP) > 15 mmHg, consistent with HFpEF, compared to only 14 of 28 (50%) negative patients.
With exercise 6 of 7 (86%) positive patients had PCWP ≥ 25 mmHg, consistent with HFpEF, compared to 11 of 20 (55%) negative patients.
At rest, positive patients had significantly higher PCWP, mean pulmonary arterial pressure (mPAP), and pulmonary vascular resistance (PVR).
After exercise, there were no significant differences in PCWP or mPAP between the two groups, but thermodilution cardiac output was significantly lower in the positive patients.
Conclusion:
Patients identified as HFpEF positive by a validated TTE-guided AI tool were more likely to have HFpEF confirmed invasively, indicating its potential for risk stratification.
However, the negative predictive value for HFpEF confirmed by invasive hemodynamics was low in this population.
Related Results
Left Atrioventricular Coupling Index in Heart Failure Patients Using Echocardiography: A Simple Yet Effective Metric
Left Atrioventricular Coupling Index in Heart Failure Patients Using Echocardiography: A Simple Yet Effective Metric
Abstract
Background
Heart failure (HF) is a global health challenge, with significant rates of hospitalization and mortality. T...
Characterizing obesity-HFpEF in younger acute respiratory failure patients
Characterizing obesity-HFpEF in younger acute respiratory failure patients
AbstractBackgroundHypoxic hypercapnic respiratory failure is a major cause of acute hospitalization. Cardiopulmonary insults can lead to respiratory distress and, if untreated, res...
Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
BackgroundHeart failure with preserved ejection fraction (HFpEF) is an increasing public health concern. Currently, data regarding the clinical application value of plasma Galectin...
Clinical and treatment perspectives for heart failure with preserved ejection fraction
Clinical and treatment perspectives for heart failure with preserved ejection fraction
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Heart failure with preserved ejection fraction (HFpEF) currently represents half of the ~6 million heart fail...
Clinical outcomes of patients with heart failure and preserved ejection fraction in Chinese
Clinical outcomes of patients with heart failure and preserved ejection fraction in Chinese
Background
Although heart failure is recognised as a major health problem, little is known about heart failure with preserved ejection fraction (HFPEF) in the Chi...
Evidence of microvascular dysfunction in heart failure with preserved ejection fraction
Evidence of microvascular dysfunction in heart failure with preserved ejection fraction
Objective
While vascular dysfunction is well defined in patients with heart failure (HF) with reduced ejection fraction (HFrEF), disease-related alterations in th...
Epicardial fat volume assessment via cardiac computed tomography: a novel indicator in heart failure with preserved ejection fraction
Epicardial fat volume assessment via cardiac computed tomography: a novel indicator in heart failure with preserved ejection fraction
Abstract
Background
Heart failure with preserved ejection fraction (HFpEF) is a complex condition characterized by high morbidity and mortality, ...
Galectin-3 in Heart Failure with Preserved Ejection Fraction and Persistent Atrial Fibrillation Versus Sinus Rhythm. Correlation with Left Atrial Volume and N-Terminal Pro B-Type Natriuretic Peptide
Galectin-3 in Heart Failure with Preserved Ejection Fraction and Persistent Atrial Fibrillation Versus Sinus Rhythm. Correlation with Left Atrial Volume and N-Terminal Pro B-Type Natriuretic Peptide
Background: Galectin-3 (Gal-3) is considered both a profibrotic biomarker in Heart Failure with preserved Ejection Fraction (HFpEF) and a biomarker of atrial remodeling in Atrial F...

